{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:08:59Z","timestamp":1792642139788,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T00:00:00Z","timestamp":1562716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T00:00:00Z","timestamp":1562716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100011019","name":"Nemzeti Kutat\u00e1si Fejleszt\u00e9si \u00e9s Innov\u00e1ci\u00f3s Hivatal","doi-asserted-by":"publisher","award":["NVKP-16-1-2016-0017"],"award-info":[{"award-number":["NVKP-16-1-2016-0017"]}],"id":[{"id":"10.13039\/501100011019","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s12032-019-1295-8","type":"journal-article","created":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T08:11:31Z","timestamp":1562746291000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Anti-cancer drugs-induced arterial injury: risk stratification, prevention, and treatment"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0074-6788","authenticated-orcid":false,"given":"Edit","family":"Gara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krist\u00f3f Gy\u00f6rgy","family":"Csik\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"Ruzsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e1bor","family":"F\u00f6ldes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9la","family":"Merkely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,10]]},"reference":[{"key":"1295_CR1","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.cjca.2015.12.023","volume":"32","author":"AC Cameron","year":"2016","unstructured":"Cameron AC, Touyz RM, Lang NN. Vascular complications of cancer chemotherapy. Can J Cardiol. 2016;32:852\u201362.","journal-title":"Can J Cardiol"},{"key":"1295_CR2","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1053\/j.seminoncol.2009.07.006","volume":"36","author":"B Hayes-Lattin","year":"2009","unstructured":"Hayes-Lattin B, Nichols CR. Testicular cancer: a prototypic tumor of young adults. Semin Oncol. 2009;36:432\u20138.","journal-title":"Semin Oncol"},{"key":"1295_CR3","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1161\/CIRCULATIONAHA.115.010484","volume":"132","author":"AM Bellinger","year":"2015","unstructured":"Bellinger AM, Arteaga CL, Force T, Humphreys BD, Demetri GD, Druker BJ, et al. Cardio-oncology. Circulation. 2015;132:2248\u201358.","journal-title":"Circulation"},{"key":"1295_CR4","first-page":"4501","volume":"31","author":"KP Dieckmann","year":"2011","unstructured":"Dieckmann KP, Struss WJ, Budde U. Evidence for acute vascular toxicity of cisplatin-based chemotherapy in patients with germ cell tumour. Anticancer Res. 2011;31:4501\u20135.","journal-title":"Anticancer Res"},{"key":"1295_CR5","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1093\/annonc\/mdp597","volume":"21","author":"K-P Dieckmann","year":"2010","unstructured":"Dieckmann K-P, Gerl A, Witt J, Hartmann J-T. Myocardial infarction and other major vascular events during chemotherapy for testicular cancer. Ann Oncol. 2010;21:1607\u201311.","journal-title":"Ann Oncol"},{"key":"1295_CR6","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1200\/JCO.2011.35.5669","volume":"29","author":"RA Moore","year":"2011","unstructured":"Moore RA, Adel N, Riedel E, Bhutani M, Feldman DR, Tabbara NE, et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol. 2011;29:3466\u201373.","journal-title":"J Clin Oncol"},{"key":"1295_CR7","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1093\/annonc\/mds527","volume":"24","author":"EC de Haas","year":"2013","unstructured":"de Haas EC, Altena R, Boezen HM, Zwart N, Smit AJ, Bakker SJL, et al. Early development of the metabolic syndrome after chemotherapy for testicular cancer. Ann Oncol. 2013;24:749\u201355.","journal-title":"Ann Oncol"},{"key":"1295_CR8","doi-asserted-by":"publisher","first-page":"4649","DOI":"10.1200\/JCO.2010.29.9362","volume":"28","author":"HS Haugnes","year":"2010","unstructured":"Haugnes HS, Wethal T, Aass N, Dahl O, Klepp O, Langberg CW, et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol. 2010;28:4649\u201357.","journal-title":"J Clin Oncol"},{"key":"1295_CR9","first-page":"42","volume":"268","author":"DL Kachel","year":"1994","unstructured":"Kachel DL, Martin WJ. Cyclophosphamide-induced lung toxicity: mechanism of endothelial cell injury. J Pharmacol Exp Ther. 1994;268:42\u20136.","journal-title":"J Pharmacol Exp Ther"},{"key":"1295_CR10","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ejphar.2017.10.043","volume":"818","author":"K Renu","year":"2018","unstructured":"Renu K, Abilash VG, Tirupathi TP, Arunachalam S. Molecular mechanism of doxorubicin-induced cardiomyopathy\u2014An update. Eur J Pharmacol. 2018;818:241\u201353.","journal-title":"Eur J Pharmacol"},{"key":"1295_CR11","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1097\/FJC.0b013e3181d263f7","volume":"55","author":"SC Wood","year":"2010","unstructured":"Wood SC, Tang X, Tesfamariam B. Paclitaxel potentiates inflammatory cytokine-induced prothrombotic molecules in endothelial cells. J Cardiovasc Pharmacol. 2010;55:276\u201385.","journal-title":"J Cardiovasc Pharmacol"},{"key":"1295_CR12","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1161\/CIRCULATIONAHA.115.018347","volume":"133","author":"J Herrmann","year":"2016","unstructured":"Herrmann J, Yang EH, Iliescu CA, Cilingiroglu M, Charitakis K, Hakeem A, et al. Vascular toxicities of cancer therapies: the old and the new - an evolving avenue. Circulation. 2016;133:1272\u201389.","journal-title":"Circulation"},{"key":"1295_CR13","first-page":"8","volume":"20","author":"I Ben Aharon","year":"2013","unstructured":"Ben Aharon I, Bar Joseph H, Tzabari M, Shenkman B, Farzam N, Levi M, et al. Doxorubicin-induced vascular toxicity - targeting potential pathways may reduce procoagulant activity. PLoS ONE. 2013;20:8.","journal-title":"PLoS ONE"},{"key":"1295_CR14","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nrc1317","volume":"4","author":"MA Jordan","year":"2004","unstructured":"Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4:253\u201365.","journal-title":"Nat Rev Cancer"},{"key":"1295_CR15","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1200\/JCO.1991.9.9.1704","volume":"9","author":"EK Rowinsky","year":"1991","unstructured":"Rowinsky EK, McGuire WP, Guarnieri T, Fisherman JS, Christian MC, Donehower RC. Cardiac disturbances during the administration of taxol. J Clin Oncol. 1991;9:1704\u201312.","journal-title":"J Clin Oncol"},{"key":"1295_CR16","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.lungcan.2006.10.016","volume":"55","author":"K Yoh","year":"2007","unstructured":"Yoh K, Niho S, Goto K, Ohmatsu H, Kubota K, Kakinuma R, et al. Randomized trial of drip infusion versus bolus injection of vinorelbine for the control of local venous toxicity. Lung Cancer. 2007;55:337\u201341.","journal-title":"Lung Cancer."},{"key":"1295_CR17","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.freeradbiomed.2009.10.032","volume":"48","author":"T Yamada","year":"2010","unstructured":"Yamada T, Egashira N, Imuta M, Yano T, Yamauchi Y, Watanabe H, et al. Role of oxidative stress in vinorelbine-induced vascular endothelial cell injury. Free Radic Biol Med. 2010;48:120\u20137.","journal-title":"Free Radic Biol Med."},{"key":"1295_CR18","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.ctrv.2013.03.005","volume":"39","author":"A Polk","year":"2013","unstructured":"Polk A, Vaage-Nilsen M, Vistisen K, Nielsen DL. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors. Cancer Treat Rev. 2013;39:974\u201384.","journal-title":"Cancer Treat Rev"},{"key":"1295_CR19","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00432-007-0250-9","volume":"134","author":"C Kosmas","year":"2008","unstructured":"Kosmas C, Kallistratos MS, Kopterides P, Syrios J, Skopelitis H, Mylonakis N, et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol. 2008;134:75\u201382.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1295_CR20","first-page":"15","volume":"4","author":"A Polk","year":"2014","unstructured":"Polk A, Vistisen K, Vaage-Nilsen M, Nielsen DL. A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity. BMC Pharmacol Toxicol. 2014;4:15\u201347.","journal-title":"BMC Pharmacol Toxicol."},{"key":"1295_CR21","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1517\/14740330802374262","volume":"7","author":"CA Dasanu","year":"2008","unstructured":"Dasanu CA. Gemcitabine: vascular toxicity and prothrombotic potential. Expert Opin Drug Saf. 2008;7:703\u201316.","journal-title":"Expert Opin Drug Saf."},{"key":"1295_CR22","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1097\/MJT.0000000000000134","volume":"23","author":"A Qasem","year":"2014","unstructured":"Qasem A, Abdulhak AAB, Aly A, Moormeier J. Capecitabine-induced Takotsubo cardiomyopathy: a case report and literature review. Am J Ther. 2014;23:1188\u201392.","journal-title":"Am J Ther"},{"key":"1295_CR23","first-page":"1","volume":"12","author":"SC Howard","year":"2016","unstructured":"Howard SC, McCormick J, Pui C-H, Buddington RK, Harvey RD. Preventing and managing toxicities of high-dose methotrexate. Oncologist. 2016;12:1\u201312.","journal-title":"Oncologist."},{"key":"1295_CR24","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrd3003","volume":"9","author":"TT Hansel","year":"2010","unstructured":"Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJT. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov. 2010;9:325\u201338.","journal-title":"Nat Rev Drug Discov."},{"key":"1295_CR25","first-page":"2","volume":"10","author":"BA Baldo","year":"2013","unstructured":"Baldo BA. Adverse events to monoclonal antibodies used for cancer therapy focus on hypersensitivity responses. Oncoimmunology. 2013;10:2.","journal-title":"Oncoimmunology."},{"key":"1295_CR26","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1038\/sj.bjc.6603813","volume":"96","author":"T Kamba","year":"2007","unstructured":"Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007;96:1788\u201395.","journal-title":"Br J Cancer"},{"key":"1295_CR27","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1200\/JCO.2009.27.2757","volume":"28","author":"TK Choueiri","year":"2010","unstructured":"Choueiri TK, Schutz FAB, Je Y, Rosenberg JE, Bellmunt J. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol. 2010;28:2280\u20135.","journal-title":"J Clin Oncol"},{"key":"1295_CR28","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s00228-014-1687-9","volume":"70","author":"WX Qi","year":"2014","unstructured":"Qi WX, Shen Z, Tang LN, Yao Y. Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups. Eur J Clin Pharmacol. 2014;70:893\u2013906.","journal-title":"Eur J Clin Pharmacol"},{"key":"1295_CR29","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","volume":"10","author":"JJ Moslehi","year":"2015","unstructured":"Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol. 2015;10:4210\u20138.","journal-title":"J Clin Oncol"},{"key":"1295_CR30","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1093\/jnci\/djr242","volume":"103","author":"E Amir","year":"2011","unstructured":"Amir E, Seruga B, Niraula S, Carlsson L, Oca\u00f1a A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 2011;103:1299\u2013309.","journal-title":"J Natl Cancer Inst"},{"key":"1295_CR31","doi-asserted-by":"publisher","first-page":"3784","DOI":"10.1200\/JCO.2009.26.3756","volume":"4","author":"HJ Burstein","year":"2010","unstructured":"Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol. 2010;4:3784\u201396.","journal-title":"J Clin Oncol"},{"key":"1295_CR32","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ejca.2016.08.022","volume":"68","author":"H Abdel-Qadir","year":"2016","unstructured":"Abdel-Qadir H, Amir E, Fischer HD, Fu L, Austin PC, Harvey PJ, et al. The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancer. Eur J Cancer. 2016;68:11\u201321.","journal-title":"Eur J Cancer"},{"issue":"11","key":"1295_CR33","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.2174\/0929867324666170407125017","volume":"25","author":"G Varricchi","year":"2017","unstructured":"Varricchi G, Marone G, Mercurio V, Bonaduce D, Tocchetti CG. Immune checkpoint inhibitors and cardiac toxicity: an emerging issue. Curr Med Chem. 2017;25(11):1327\u201339.","journal-title":"Curr Med Chem"},{"key":"1295_CR34","first-page":"50","volume":"15","author":"P Darvin","year":"2018","unstructured":"Darvin P, Toor SM, Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018;15:50.","journal-title":"Exp Mol Med"},{"key":"1295_CR35","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/sj.leu.2405062","volume":"22","author":"A Palumbo","year":"2008","unstructured":"Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22:414\u201323.","journal-title":"Leukemia"},{"issue":"4","key":"1295_CR36","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1200\/JCO.2012.43.2872","volume":"31","author":"SE McGrath","year":"2013","unstructured":"McGrath SE, Webb A, Walker-Bone K. Bleomycin-induced Raynaud\u2019s phenomenon after single-dose exposure: risk factors and treatment with intravenous iloprost infusion. J Clin Oncol. 2013;31(4):e51\u20132.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1295_CR37","first-page":"41","volume":"28","author":"V Gr\u00fcnwald","year":"2005","unstructured":"Gr\u00fcnwald V, Bolte O, Wiebe S, Ganser A, Sch\u00f6ffski P. Acral necrosis after inadequate excessive administration of bleomycin in a testicular cancer patient. Onkologie. 2005;28(1):41\u20133.","journal-title":"Onkologie"},{"key":"1295_CR38","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"74","author":"JL Zamorano","year":"2016","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Mu\u00f1oz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J. 2016;74:2768\u2013801.","journal-title":"Eur Heart J"},{"key":"1295_CR39","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1200\/JCO.2013.49.1118","volume":"31","author":"GH Lyman","year":"2013","unstructured":"Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31:2189\u2013204.","journal-title":"J Clin Oncol"},{"key":"1295_CR40","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.cjca.2016.02.078","volume":"32","author":"SA Virani","year":"2016","unstructured":"Virani SA, Dent S, Brezden-Masley C, Clarke B, Davis MK, Jassal DS, et al. Canadian Cardiovascular Society guidelines for evaluation and management of cardiovascular complications of cancer therapy. Can J Cardiol. 2016;32:831\u201341.","journal-title":"Can J Cardiol"},{"key":"1295_CR41","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","volume":"111","author":"AA Khorana","year":"2008","unstructured":"Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111:4902\u20137.","journal-title":"Blood"},{"key":"1295_CR42","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ejca.2016.05.022","volume":"63","author":"S Lubberts","year":"2016","unstructured":"Lubberts S, Boer H, Altena R, Meijer C, Van Roon AM, Zwart N, et al. Vascular fingerprint and vascular damage markers associated with vascular events in testicular cancer patients during and after chemotherapy. Eur J Cancer. 2016;63:180\u20138.","journal-title":"Eur J Cancer"},{"key":"1295_CR43","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ejca.2016.10.003","volume":"69","author":"M Gizzi","year":"2016","unstructured":"Gizzi M, Oberic L, Massard C, Poterie A, Gwenael LT, Loriot Y, et al. Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours. Eur J Cancer. 2016;69:151\u20137.","journal-title":"Eur J Cancer"},{"issue":"3","key":"1295_CR44","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s11739-012-0784-y","volume":"7","author":"M Verso","year":"2012","unstructured":"Verso M, Agnelli G, Barni S, Gasparini G, LaBianca R. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med. 2012;7(3):291\u20132.","journal-title":"Intern Emerg Med"},{"key":"1295_CR45","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.1200\/JCO.2014.60.3654","volume":"33","author":"C Fung","year":"2015","unstructured":"Fung C, Fossa SD, Milano MT, Sahasrabudhe DM, Peterson DR, Travis LB. Cardiovascular disease mortality after chemotherapy or surgery for testicular nonseminoma: a population-based study. J Clin Oncol. 2015;33:3106\u201314.","journal-title":"J Clin Oncol"},{"key":"1295_CR46","doi-asserted-by":"publisher","first-page":"9130","DOI":"10.1200\/JCO.2005.01.4092","volume":"23","author":"J Nuver","year":"2005","unstructured":"Nuver J, Smit AJ, Van Der Meer J, Van Den Berg MP, Van Der Graaf WTA, Meinardi MT, et al. Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J Clin Oncol. 2005;23:9130\u20137.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1295_CR47","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1479-5876-9-179","volume":"9","author":"S Barni","year":"2011","unstructured":"Barni S, Labianca R, Agnelli G, Bonizzoni E, Verso M, Mandal\u00e0 M, et al. Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. J Transl Med. 2011;9(1):79.","journal-title":"J Transl Med"},{"key":"1295_CR48","first-page":"457","volume":"147","author":"ME Brouha","year":"2003","unstructured":"Brouha ME, Bloemendal HJ, Kappelle LJ, Winter JB. Cerebral infarction and myocardial infarction due to cisplatin-containing chemotherapy. Ned Tijdschr Geneeskd. 2003;147:457\u201360.","journal-title":"Ned Tijdschr Geneeskd"},{"key":"1295_CR49","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1186\/1471-2407-9-459","volume":"9","author":"KP Dieckmann","year":"2009","unstructured":"Dieckmann KP, Gehrckens R. Thrombosis of abdominal aorta during cisplatin-based chemotherapy of testicular seminoma\u2013a case report. BMC Cancer. 2009;9:459.","journal-title":"BMC Cancer."},{"key":"1295_CR50","first-page":"1","volume":"2011","author":"SW Yusuf","year":"2011","unstructured":"Yusuf SW, Sami S, Daher IN. Radiation-induced heart disease: a clinical update. Cardiol Res Pract. 2011;2011:1\u20139.","journal-title":"Cardiol Res Pract."}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-019-1295-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-019-1295-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-019-1295-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T23:32:27Z","timestamp":1594251147000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-019-1295-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,10]]},"references-count":50,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["1295"],"URL":"https:\/\/doi.org\/10.1007\/s12032-019-1295-8","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,10]]},"assertion":[{"value":"10 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"72"}}